PDF(Pubmed)
Abstract：
UNASSIGNED: Alectinib, a highly potent, highly selective, brain-penetrant anaplastic lymphoma kinase (ALK) inhibitor is now the first line therapy for patients with metastatic ALK-positive non small cell lung cancer (NSCLC).
UNASSIGNED: We report a rare case of pneumoperitoneum following alectinib initiation for metastatic non small cell lung cancer in a 74-year-old African American female. Patient developed abdominal pain approximately 2 weeks after starting alectinib. She was hemodynamically stable, and imaging revealed pneumoperitoneum. Patient was successfully managed non-operatively.
UNASSIGNED: Gastrointestinal perforation presenting as pneumoperitoneum is a very rare complication of alectinib. To our knowledge our patient is only the second case to be reported in the literature since its approval. The complication is likely attributable to the rapid tumor regression in the gastrointestinal tract. Non-operative management should be attempted if possible.
UNASSIGNED: Oncologists should be aware of the risk of gastrointestinal perforation when initiating cytotoxic chemotherapy on patients with metastatic NSCLC. A multidisciplinary approach is critical in appropriately individualizing care in this patient population.
UNASSIGNED: We report a rare case of pneumoperitoneum following alectinib initiation for metastatic non small cell lung cancer in a 74-year-old African American female. Patient developed abdominal pain approximately 2 weeks after starting alectinib. She was hemodynamically stable, and imaging revealed pneumoperitoneum. Patient was successfully managed non-operatively.
UNASSIGNED: Gastrointestinal perforation presenting as pneumoperitoneum is a very rare complication of alectinib. To our knowledge our patient is only the second case to be reported in the literature since its approval. The complication is likely attributable to the rapid tumor regression in the gastrointestinal tract. Non-operative management should be attempted if possible.
UNASSIGNED: Oncologists should be aware of the risk of gastrointestinal perforation when initiating cytotoxic chemotherapy on patients with metastatic NSCLC. A multidisciplinary approach is critical in appropriately individualizing care in this patient population.
摘要：
未经批准：阿莱替尼，一个非常强大的，高度选择性,脑穿透性间变性淋巴瘤激酶(ALK)抑制剂现在是转移性ALK阳性非小细胞肺癌(NSCLC)患者的一线治疗方法.
UNASSIGNED：我们报告了一名74岁的非裔美国女性在阿来替尼开始治疗转移性非小细胞肺癌后发生气腹的罕见病例。患者在开始阿来替尼后约2周出现腹痛。她血液动力学稳定,影像学显示气腹。患者非手术治疗成功。
未经证实：表现为气腹的胃肠道穿孔是阿来替尼的一种非常罕见的并发症。据我们所知，我们的患者仅是自批准以来文献中报告的第二例。并发症可能归因于胃肠道中的快速肿瘤消退。如果可能，应尝试非手术管理。
UNASSIGNED：肿瘤学家在对转移性NSCLC患者进行细胞毒性化疗时，应该意识到胃肠道穿孔的风险。多学科方法对于在该患者人群中适当地个性化护理至关重要。
UNASSIGNED：我们报告了一名74岁的非裔美国女性在阿来替尼开始治疗转移性非小细胞肺癌后发生气腹的罕见病例。患者在开始阿来替尼后约2周出现腹痛。她血液动力学稳定,影像学显示气腹。患者非手术治疗成功。
未经证实：表现为气腹的胃肠道穿孔是阿来替尼的一种非常罕见的并发症。据我们所知，我们的患者仅是自批准以来文献中报告的第二例。并发症可能归因于胃肠道中的快速肿瘤消退。如果可能，应尝试非手术管理。
UNASSIGNED：肿瘤学家在对转移性NSCLC患者进行细胞毒性化疗时，应该意识到胃肠道穿孔的风险。多学科方法对于在该患者人群中适当地个性化护理至关重要。
